ISIS REPORTS DATA FROM CARDIOVASCULAR DISEASE STUDY

Isis Pharmaceuticals has reported additional data from clinical studies of ISIS 301012 that continue to broaden the potential profile for the drug to treat patients with cardiovascular disease. In a drug-drug interaction study, ISIS 301012 did not interact with simvastatin or ezetimibe, currently available lipid lowering drugs with which ISIS 301012 may be dosed in combination. In this study and consistent with the growing body of data on ISIS 301012, the drug also reduced cholesterol, LDL-C, and was well-tolerated.

ISIS 301012, a second-generation antisense drug, inhibits apoB-100, a protein critical to the synthesis and transport of the "bad" cholesterol involved in heart disease - low-density lipoprotein cholesterol and very low-density lipoprotein (VLDL). Lowering cholesterol and triglyceride levels is a key component to the prevention and management of cardiovascular disease.